[Gefitinib therapy in non-small-cell lung cancer].
Jänne
Pasi A
PA
Harvard Medical School, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA. pjanne@partners.org
D014408:Biomarkers, Tumor / Q000032:analysis; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D005387:Finland; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D011379:Prognosis; D011799:Quinazolines / Q000008:administration & dosage*; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib